NEW YORK, NY - June 5, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (“Fulcrum Therapeutics” or the “Company”) (NASDAQ: FULC).

CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION

If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing jcampisi@kaplanfox.com or by calling (212) 329-8571.

Fulcrum Therapeutics is a “clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with rare hematological disorders[.]”

On June 1, 2026, after market close, Fulcrum Therapeutics announced in a press release “the discontinuation of its pociredir program for the treatment of SCD [(sickle cell disease).]” The Company stated that the “meeting minutes from recent end-of-phase interactions with the [U.S. Food and Drug Administration (“FDA”)]” “reflected heightened FDA concerns regarding pociredir's benefit-risk profile in SCD, stemming from an unexpectedly high rate of secondary hematologic malignancies observed with Tazverik® (tazemetostat), another PRC2 inhibitor, which was withdrawn from the global market in March 2026.” After submitting further information, the FDA “concluded that any pharmacological intervention targeting the PRC2 complex carries equivalent malignancy risk regardless of the specific subunit engaged.”  As a result, the Company has “no viable regulatory path forward for further clinical development of pociredir.”

Following this news, the price of Fulcrum Therapeutics stock declined from a closing price on June 1, 2026 of $6.42 per share to close at $3.14 per share on June 2, 2026, a decline of $3.28 per share, or by 51.09%.

WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey.  With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand.  Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients.  For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

If you have any questions about this investigation, please contact:

CONTACT:
Jeffrey P. Campisi
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(212) 329-8571
jcampisi@kaplanfox.com

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1501
Oakland, California 94612
(415) 772-4704
lking@kaplanfox.com

Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.

https://www.kaplanfox.com/case/fulcrum-therapeutics-inc-investigation-learn-more-now/

View the original release on www.newmediawire.com